Table 1.
Characteristics of the participants
| Overall (n = 4721) | Male (n = 1787) | Female (n = 2934) | P Value | |
|---|---|---|---|---|
| Age, yeara | 64.4 ± 12.0 | 69.9 ± 6.3 | 61.1 ± 13.3 | < 0.001 |
| TyG Index | 8.6 ± 0.6 | 8.6 ± 0.5 | 8.6 ± 0.6 | = 0.201 |
| Height, cma | 159.3 ± 8.1 | 166.0 ± 5.8 | 155.2 ± 6.4 | < 0.001 |
| Body weight, kga | 57.7 ± 6.8 | 62.9 ± 5.8 | 54.5 ± 5.3 | < 0.001 |
| Body mass index, kg/m2a | 22.7 ± 1.4 | 22.8 ± 1.3 | 22.6 ± 1.4 | < 0.001 |
| Waist circumference, cma | 80.6 ± 6.5 | 84.3 ± 5.6 | 78.3 ± 6.0 | < 0.001 |
| SBP, mm Hg | 119.7 ± 16.7 | 119.9 ± 16.6 | 119.6 ± 16.8 | = 0.450 |
| DBP, mm Hg | 75.4 ± 10.0 | 75.6 ± 9.9 | 75.3 ± 10.0 | = 0.329 |
| FPG, mg/dL | 99.9 ± 19.2 | 99.9 ± 19.0 | 99.9 ± 19.3 | = 0.965 |
| HDLC, mg/dL | 51.1 ± 12.6 | 51.0 ± 12.3 | 51.1 ± 12.8 | = 0.747 |
| Triglyceride, mg/dL | 124.3 ± 67.4 | 125.3 ± 66.1 | 123.8 ± 68.2 | = 0.453 |
| Medication | ||||
| Antihypertensive medication, n (%) | 1611 (34.1) | 725 (40.6) | 886 (30.2) | < 0.001 |
| Lipid-lowering medication, n (%) | 832 (17.6) | 267 (14.9) | 565 (19.3) | < 0.001 |
| Antihyperglycemic medication, n (%) | 664 (14.1) | 328 (18.4) | 336 (11.5) | < 0.001 |
| Chronic disease prevalence | ||||
| Non-alcoholic fatty liver disease, n (%) | 415 (8.8) | 98 (5.5) | 317 (10.8) | < 0.001 |
| T2DM, n (%) | 1053 (22.3) | 473 (26.5) | 580 (19.8) | < 0.001 |
| Hypertension, n (%) | 2578 (54.6) | 1078 (60.3) | 1500 (51.1) | < 0.001 |
Values are mean ± SD
Abbreviations: DBP diastolic blood pressure, FPG fasting plasma glucose, HDLC high-density lipoprotein-cholesterol, SBP systolic blood pressure, TyG triglyceride-glucose, T2DM type 2 diabetes mellitus
aThe Mann–Whitney U-test was used to assess the difference between groups